1Skovronsky DM, Lee VM, Trojanowski JQ. Neurodegenerative diseases: new concepts of pathogencsis and their therapeutic implications. Annu Rev Pathol, 2006;1:151 -170.
2Masters CL, Simms G, Weinman NA et al. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sei USA, 1985 ;82:4245 -4249.
3Zhou XW, Tanila H, Pei JJ. Parallel increase in p70 kinase activation and tau phosphorylation ($262) with Aβ overproduction. FEBS Lett, 2008 ;582:159 - 164.
4Lambert MP, Barlow AK, Chromy BA et al. Diffusible, nonfibrillar ligands derived from A betal-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci USA, 1998 ;95:6448 -6453.
5Butterfield DA, Reed T, Newman SF et al. Roles of amyloid β-peptide-associated oxidative stress and brain protein modifications in the pathogenesis of Alzheimer's disease and mild cognitive impairment. Free Radic Biol Med, 2007 ;43:658 -677.
6Zana M, Janka Z, Kalman J. Oxidative stress: A bridge between Down's syndrome and Alzheimer's disease. Neurobiol Aging, 2007 ;28:648 -676.
7Cole SL, Vassar R. BACE1 structure and function in health and Alzheimer's disease. Curr Alzheimer Res, 2008 ;5 : 100 - 120.
8Ghosh AK, Kumaraqurubaran N, Hong Let al. Memapsin 2 ( beta- secretase ) inhibitors : drug development. Curr Alzheimer Res, 2008 ;5 : 121 - 131.
9Tun H, Marlow L, Pinnix I et al. Lipid rafts play an important role in A beta biogenesis by resulating the beta-secretase pathway. J Mol Neurosei, 2002 ; 19:31 - 35.
10De Strooper B. Aph-1, Pen-2, and Nieastrin with presenilin generate an active gamma-seeretase complexes. Neuron, 2003 ;38:9 - 12.
